Cell & Gene Covers the Session, Early Regulatory Alignment to Implement Next-Generation Sequencing at GMP Scale, to be Presented at the 2026 ISPE Annual Meeting & Expo

13 October, 2026

As cell and gene therapy developers seek faster, more comprehensive approaches to viral safety testing, next-generation sequencing (NGS) is emerging as a promising technology for detecting adventitious agents at GMP scale. The topic will be explored at the 2026 ISPE Annual Meeting & Expo, where Jihye Nam and Tracie Fradet of Astellas Pharma will discuss the opportunities and challenges associated with implementing NGS-based viral safety testing in regulated manufacturing environments.

Traditional adventitious agent detection methods have long served as a cornerstone of biopharmaceutical safety, but they present several limitations. Cell culture-based assays can require weeks to generate results and depend on a virus's ability to infect specific indicator cells. Molecular assays offer faster turnaround times but generally require prior knowledge of the viral sequences being targeted. As a result, these approaches may struggle to detect unknown or unexpected contaminants and often require multiple complementary tests to achieve broad coverage.

NGS offers a fundamentally different approach. Rather than searching for predefined viral targets, the technology enables broad, hypothesis-free screening for a wide range of known and potentially novel viruses in a single assay. According to Nam and Fradet, this capability provides significant advantages for cell and gene therapy manufacturers, offering high sensitivity, scalability, and the ability to generate extensive safety information from limited sample volumes.

The need for improved detection methods is particularly important in cell and gene therapy manufacturing. Unlike many traditional biologic products, cell therapies often contain large amounts of host-cell DNA and RNA, creating substantial biological background noise that can obscure low-level viral contamination signals. In addition, developers frequently have very limited sample quantities available, especially when testing valuable cell banks, intermediates, or final drug products. Because each test may consume a meaningful portion of a manufacturing lot, maximizing the amount of information obtained from each sample becomes critical. NGS allows manufacturers to evaluate a broad spectrum of viral risks while minimizing sample consumption, an increasingly important advantage for advanced therapies.

However, implementing NGS in GMP environments is not as simple as replacing existing assays. Cell and gene therapy processes often utilize complex materials such as viral vectors, plasmids, and cytokines, all of which can leave residual nucleic acid signatures that may appear during sequencing analyses. As a result, detecting a viral sequence does not automatically indicate the presence of an infectious contaminant. Interpreting results accurately requires sophisticated bioinformatics tools, robust risk assessments, and a thorough understanding of the manufacturing process.

A major theme of the article is the importance of early engagement with regulators. Through industry consortia and working groups, many organizations have aligned around a strategy of first developing and validating an NGS method and then seeking regulatory feedback before incorporating it into GMP testing programs. Astellas Pharma followed this approach by engaging the US Food and Drug Administration (US FDA) through a Type D meeting to discuss validation plans and implementation strategies. Industry groups have also promoted harmonization through shared tools such as the First World Health Organization International Reference Panel for Adventitious Virus Detection and the Reference Viral Database (RVDB), helping companies establish more consistent validation and reporting practices.

According to Nam and Fradet, regulators are increasingly focused on validating the entire NGS workflow rather than just sequencing performance. Discussions typically cover sample preparation methods, nucleic acid extraction, sequencing strategies, bioinformatics pipelines, reference databases, control strategies, and procedures for investigating positive findings. Regulators also expect companies to explain how they will address detections involving novel or poorly characterized viral sequences that may not be represented in current databases.

While regulatory agencies such as the US FDA and Japan’s Pharmaceuticals and Medical Devices Agency generally ask similar scientific questions, some differences remain regarding the extent to which NGS can replace traditional assays. Agencies broadly support risk-based, fit-for-purpose validation approaches and recognize the value of NGS within broader viral safety programs. However, complete replacement of conventional adventitious virus testing is still viewed cautiously, with expectations continuing to evolve as more validation data becomes available across the industry.

One of the most significant technical challenges is validating a method intended to detect unknown viral threats. Rather than proving detection of a single predefined target, developers must demonstrate that the overall system can reliably identify a broad range of virus types. This requires validation panels representing diverse viral families, including DNA and RNA viruses, enveloped and non-enveloped viruses, and a range of genome structures and sizes. Equally important is maintaining robust, well-curated reference databases capable of supporting sequence classification and highlighting unusual findings that warrant further investigation.

The investment required to implement NGS can be substantial. For Astellas Pharma, development and validation of an NGS-based adventitious agent detection platform required approximately 12 to 15 months, including assay optimization, validation activities, and qualification of bioinformatics systems. Yet once established, the benefits can be significant. NGS can consolidate multiple traditional assays into a single workflow, reducing laboratory burden, minimizing cleanroom utilization, and accelerating viral safety assessments.

Looking ahead, Nam and Fradet believe the value of NGS extends beyond adventitious virus detection. For genetically engineered cell therapies, sequencing technologies may eventually function as multi-attribute analytical methods capable of addressing several quality and safety questions from a single analysis. Such capabilities could improve process understanding, reduce testing complexity, and support more efficient manufacturing operations.

Despite growing momentum, several challenges remain. Organizations must maintain validated software systems, manage large data volumes, implement cybersecurity controls, and continuously update bioinformatics tools and databases. They must also recruit and train staff with expertise spanning molecular biology, sequencing technologies, bioinformatics, and regulatory compliance. Additionally, the industry continues to work toward standardized approaches for investigating and interpreting positive findings, particularly when highly sensitive NGS systems identify low-level signals whose clinical significance is uncertain.

As discussions at the 2026 ISPE Annual Meeting & Expo are expected to highlight, next-generation sequencing has the potential to transform viral safety testing in cell and gene therapy manufacturing. By enabling comprehensive detection of known and novel viral threats while reducing testing complexity and sample consumption, NGS is increasingly positioned as a key technology for the future of GMP manufacturing. Success, however, will depend on continued regulatory collaboration, robust validation strategies, and the development of practical frameworks for interpreting the wealth of data these systems generate.

Read the full article

Learn More About the 2026 ISPE Annual Meeting & Expo


About Cell & Gene

Cell & Gene delivers in-depth content about cell and gene therapies from experienced professionals in the field. This publication focuses exclusively on this segment of the life sciences industry.